GB:0RV2 Stock Latest News
Company AnnouncementsReal-World Leqembi Data Show 76% Lower Dementia Progression Rate3d ago
Company AnnouncementsBioArctic Announces November 25 Webcast for Third-Quarter Report4d ago
Company AnnouncementsFive-year Leqembi data show increasing benefit over time5d ago
Company AnnouncementsLeqembi Pen Subcutaneous Treatment Launches in Japan1w ago
Company AnnouncementsNovartis Terminates BioArctic BrainTransporter Collaboration2w ago
Company AnnouncementsBioArctic Sets High-Influence Nomination Committee Ahead of 2027 AGM3w ago
Company AnnouncementsBioArctic’s Leqembi Begins First Real-World Use in Sweden After EU Approval2M ago
Company AnnouncementsJapan Approves At-Home Leqembi Pen for Early Alzheimer’s Treatment2M ago
Company AnnouncementsBioArctic Partner Eisai Wins China Approval for At-Home Leqembi Alzheimer’s Autoinjector2M ago
Company AnnouncementsBioArctic’s Leqembi Wins Key Canadian Reimbursement Backing2M ago
Company AnnouncementsBioArctic Updates Share and Vote Structure After Stock Option Exercise2M agoCompany AnnouncementsBioArctic Deepens Alzheimer’s Footprint With Leqembi Expansion and New Strategic Alliances2M ago
Company AnnouncementsBioArctic and Eisai Expand At-Home Alzheimer’s Treatment With U.S. Launch of Leqembi Iqlik2M ago
Pre-EarningsB9A Upcoming Earnings Report: What to Expect?3M ago
Company AnnouncementsBioArctic and Mesenkia team up on novel glioblastoma therapy3M ago
Company AnnouncementsBioArctic schedules August 26 webcast for Q2 2026 report3M ago
Company AnnouncementsBioArctic’s Leqembi Royalties Surge on Strong Global Q2 Sales3M ago
Company AnnouncementsReal-World Study Backs Long-Term Stability on BioArctic–Eisai Alzheimer’s Drug Leqembi4M agoCompany AnnouncementsBioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s4M ago
Company AnnouncementsSubcutaneous Leqembi Autoinjector Matches IV Exposure, Promises More Flexible Alzheimer’s Care4M ago

